Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Assets

Latest as of March 2026: CN¥10.69 Billion CNY ≈ $1.56 Billion USD

Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) holds total assets worth CN¥10.69 Billion CNY (≈ $1.56 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Assets Trend (2013–2025)

This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 603707 market cap overview for the company's overall valuation and market capitalisation.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets of CN¥10.69 Billion consist of 72.7% current assets and 27.3% non-current assets. Review 603707 total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	13.5%
Accounts Receivable	CN¥1.22 Billion	11.8%
Inventory	CN¥3.26 Billion	31.6%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥1.18 Billion	11.5%
Goodwill	CN¥126.64 Million	1.2%

Asset Composition Trend (2013–2025)

This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 603707 share price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's current assets represent 72.7% of total assets in 2025, a decrease from 73.8% in 2013.
Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 26.8% in 2013.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 1.0% in 2013.
Asset Diversification: The largest asset category is inventory at 31.6% of total assets.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Beijing Tongrentang Co Ltd SHG:600085	China	CN¥29.95 Billion
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	China	CN¥17.01 Billion
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	China	CN¥13.98 Billion
Shenzhen Kangtai Biological Products Co Ltd SHE:300601	China	CN¥13.93 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	China	CN¥6.74 Billion
Sun Pharma Advanced Research Company Limited NSE:SPARC	India	Rs3.22 Billion
ChengDa Pharmaceuticals Co. Ltd. SHE:301201	China	CN¥2.35 Billion

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.27	4.55	2.29
Quick Ratio	1.40	2.09	0.85
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥4.42 Billion	CN¥4.89 Billion	CN¥4.31 Billion

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.74
Latest Market Cap to Assets Ratio	0.18
Asset Growth Rate (YoY)	8.8%
Total Assets	CN¥10.34 Billion
Market Capitalization	$1.82 Billion USD

Valuation Analysis

Below Book Valuation: The market values Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)

The table below shows the annual total assets of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥10.34 Billion ≈ $1.51 Billion	+8.75%
2024-12-31	CN¥9.51 Billion ≈ $1.39 Billion	-0.15%
2023-12-31	CN¥9.52 Billion ≈ $1.39 Billion	-4.85%
2022-12-31	CN¥10.01 Billion ≈ $1.46 Billion	+21.82%
2021-12-31	CN¥8.22 Billion ≈ $1.20 Billion	+6.43%
2020-12-31	CN¥7.72 Billion ≈ $1.13 Billion	+52.02%
2019-12-31	CN¥5.08 Billion ≈ $743.13 Million	+49.26%
2018-12-31	CN¥3.40 Billion ≈ $497.87 Million	+26.26%
2017-12-31	CN¥2.69 Billion ≈ $394.33 Million	+76.97%
2016-12-31	CN¥1.52 Billion ≈ $222.82 Million	+17.37%
2015-12-31	CN¥1.30 Billion ≈ $189.85 Million	-15.76%
2014-12-31	CN¥1.54 Billion ≈ $225.37 Million	+33.08%
2013-12-31	CN¥1.16 Billion ≈ $169.34 Million	--

About Nanjing King-friend Biochemical Pharmaceutical Co Ltd

SHG:603707 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.82 Billion

CN¥12.44 Billion CNY

Market Cap Rank

#6517 Global

#1307 in China

Share Price

CN¥7.70

Change (1 day)

-2.65%

52-Week Range

CN¥6.84 - CN¥10.47

All Time High

CN¥33.62